Literature DB >> 7477265

Follicular dendritic cells and human immunodeficiency virus infectivity.

S L Heath1, J G Tew, J G Tew, A K Szakal, G F Burton.   

Abstract

Large amounts of human immunodeficiency virus (HIV) localize on follicular dendritic cells (FDC) in the follicles of secondary lymphoid tissues following viral infection. During clinical latency, active viral infection occurs primarily at these sites. As HIV on FDC is in the form of immune complexes, some of which may be formed with neutralizing antibody, we investigated whether HIV on FDC is infectious. We report here that HIV on FDC is highly infectious. Furthermore, FDC can convert neutralized HIV into an infectious form even in the presence of a vast excess of neutralizing antibody. Thus FDC may provide a mechanism whereby HIV infection can continue in the presence of neutralizing antibody.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7477265     DOI: 10.1038/377740a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  92 in total

1.  Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes.

Authors:  J J Jakubik; M Saifuddin; D M Takefman; G T Spear
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis.

Authors:  W S Hlavacek; C Wofsy; A S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

3.  B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1.

Authors:  J J Jakubik; M Saifuddin; D M Takefman; G T Spear
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

4.  Reservoirs for HIV-1.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

5.  Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy.

Authors:  W S Hlavacek; N I Stilianakis; D W Notermans; S A Danner; A S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

6.  CD4-Negative cells bind human immunodeficiency virus type 1 and efficiently transfer virus to T cells.

Authors:  G G Olinger; M Saifuddin; G T Spear
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2.

Authors:  L Kacani; W M Prodinger; G M Sprinzl; M G Schwendinger; M Spruth; H Stoiber; S Döpper; S Steinhuber; F Steindl; M P Dierich
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virus-specific CTL.

Authors:  Elizabeth Connick; Joy M Folkvord; Katherine T Lind; Eva G Rakasz; Brodie Miles; Nancy A Wilson; Mario L Santiago; Kimberly Schmitt; Edward B Stephens; Hyeon O Kim; Reece Wagstaff; Shengbin Li; Hadia M Abdelaal; Nathan Kemp; David I Watkins; Samantha MaWhinney; Pamela J Skinner
Journal:  J Immunol       Date:  2014-10-31       Impact factor: 5.422

9.  Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.

Authors:  Thomas J Ketas; Ines Frank; Per Johan Klasse; Brian M Sullivan; Jason P Gardner; Catherine Spenlehauer; Mirjana Nesin; William C Olson; John P Moore; Melissa Pope
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 bound to B cells: relationship to virus replicating in CD4+ T cells and circulating in plasma.

Authors:  Angela Malaspina; Susan Moir; David C Nickle; Eileen T Donoghue; Kisani M Ogwaro; Linda A Ehler; Shuying Liu; Jo Ann M Mican; Mark Dybul; Tae-Wook Chun; James I Mullins; Anthony S Fauci
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.